公开(公告)号：US11707488B2

公开(公告)日：2023-07-25

申请号：US15755859

申请日：2016-08-29

Applicant: ROHTO PHARMACEUTICAL CO., LTD.

Inventor： Yoshifumi Ikeyama ,  Hiroyuki Nishida ,  Tomohiro Tsuda ,  Eiko Uno ,  Masayo Yumoto ,  Kazuma Suda ,  Mihoko Yoshino ,  Xuan Trung Ngo

IPC: A61K35/28 ,  C12N5/0775

CPC classification number: A61K35/28 ,  C12N5/0662 ,  C12N2501/998 ,  C12N2510/00 ,  Y02A50/30

Abstract: An object of the present invention is to provide novel mesenchymal stem cells demonstrating superior therapeutic effects against various diseases, a novel pharmaceutical composition containing these mesenchymal stem cells, and a method for preparing the same. The present invention relates to ROR1-positive mesenchymal stem cells. The ROR1-positive mesenchymal stem cells are preferably positive for CD29, CD73, CD90, CD105 and CD166 and are derived from umbilical cord or adipose tissue.

公开(公告)号：US20180333436A1

公开(公告)日：2018-11-22

申请号：US15755859

申请日：2016-08-29

Applicant: ROHTO PHARMACEUTICAL CO., LTD.

Inventor： Yoshifumi Ikeyama ,  Hiroyuki Nishida ,  Tomohiro Tsuda ,  Eiko Uno ,  Masayo Yumoto ,  Kazuma Suda ,  Mihoko Yoshino ,  Xuan Trung Ngo

IPC: A61K35/28 ,  C12N5/0775

CPC classification number: A61K35/28 ,  C12N5/0662 ,  C12N2501/998 ,  C12N2510/00 ,  Y02A50/411

Abstract: An object of the present invention is to provide novel mesenchymal stem cells demonstrating superior therapeutic effects against various diseases, a novel pharmaceutical composition containing these mesenchymal stem cells, and a method for preparing the same. The present invention relates to ROR1-positive mesenchymal stem cells. The ROR1-positive mesenchymal stem cells are preferably positive for CD29, CD73, CD90, CD105 and CD166 and are derived from umbilical cord or adipose tissue.

公开(公告)号：US20200069740A1

公开(公告)日：2020-03-05

申请号：US16491974

申请日：2018-03-08

Applicant: ROHTO PHARMACEUTICAL CO., LTD.

Inventor： Hikari Hasegawa ,  Masayo Yumoto ,  Yoshifumi Ikeyama ,  Hiroyuki Nishida ,  Tomohiro Tsuda ,  Eiko Uno ,  Kazuma Suda ,  Mihoko Yoshino ,  Xuan Trung Ngo

IPC: A61K35/28

Abstract: The purpose of the present invention is to provide the following: novel mesenchymal stem cells having an excellent therapeutic effect on various diseases, particularly diseases associated with fibrosis; and a pharmaceutical composition containing such mesenchymal stem cells. The present invention is a therapeutic agent for fibrosis that contains ROR1-positive mesenchymal stem cells and/or a culture supernatant thereof and that is for preventing or treating a disease associated with fibrosis. The mesenchymal stem cells are CD29-, CD73-, CD90-, CD105-, and CD166-positive and are preferably derived from the umbilical cord or fat. In addition, the abovementioned disease associated with fibrosis is preferably a liver disease, a lung disease, a kidney disease, or a heart disease.

公开(公告)号：US20180161262A1

公开(公告)日：2018-06-14

申请号：US15577552

申请日：2016-05-26

Applicant: ROHTO PHARMACEUTICAL CO., LTD.

Inventor： Tomohiro Tsuda ,  Masayo Yumoto

IPC: A61K8/65 ,  A61Q19/00 ,  A61K8/64 ,  A61K8/34 ,  G01N33/50

CPC classification number: A61K8/65 ,  A61K8/345 ,  A61K8/64 ,  A61K38/06 ,  A61K38/07 ,  A61K2800/592 ,  A61K2800/78 ,  A61Q19/00 ,  G01N33/502 ,  G01N33/5029 ,  G01N33/5073

Abstract: The present invention relates to a cosmetic method comprising applying a migration imparting agent for adipose-derived stem cells to the skin, thereby allowing adipose-derived stem cells to migrate to the dermal layer and improving a skin condition. The present invention also relates to an external skin preparation for use in the cosmetic method, the external skin preparation comprising a migration imparting agent allowing adipose-derived stem cells to migrate to the dermal layer by application to the skin. The present invention further relates to a migration imparting agent for adipose-derived stem cells, comprising at least one of a polyol compound and a hydrophilic biomaterial. The present invention further relates to a method of screening for a component for use in a cosmetic method for improving a skin condition, comprising evaluating migratory activity of adipose-derived stem cells by using a prepared medium containing a sample.